Электронный архив

Solid cancers after antiplatelet therapy: Confirmations, controversies, and challenges

Показать сокращенную информацию

dc.contributor.author Serebruany V.
dc.contributor.author Cherepanov V.
dc.contributor.author Cabrera-Fuentes H.
dc.contributor.author Kim M.
dc.date.accessioned 2018-09-18T20:08:49Z
dc.date.available 2018-09-18T20:08:49Z
dc.date.issued 2015
dc.identifier.issn 0340-6245
dc.identifier.uri https://dspace.kpfu.ru/xmlui/handle/net/136967
dc.description.abstract © Schattauer 2015. The role of anticoagulants and antiplatelet agents in tumour growth and prognosis is not new, and currently under intense investigation. Some randomised data strongly suggest that this association exists, but it is complex, and not necessarily pointed at the same direction. The potential mechanisms responsible for such harmful association include a direct hazard of novel antithrombotics on cancer, indirect promotion of tumour growth, easier metastatic dissemination due to instability of platelet-tumour cell aggregates, or/and inability to keep cancer cells locally in situ are considered. The latest randomised evidence ultimately rejected the drug-specific cancer risks, clearly indicating the class-effect. In lay terms “cancers follow bleeding”, which seems to be true for antithrombotic agents in general. Significant excess of solid cancers which was similar after prasugrel in TRITON, and with vorapaxar in TRACER trials was confirmed by the FDA reviews. Later, extra cancer deaths reported following clopidogrel and prasugrel in DAPT, and after ticagrelor in PEGASUS are also of concern. However, there are remaining controversies with regard to published cancer risks after ticagrelor (PLATO), or another vorapaxar trial (TRA2P), while full disclosure of separate clopidogrel and prasugrel cancer data in DAPT is still lacking. In short, if we apply moderate antiplatelet strategies for over two years, or aggressive regimens including triple therapy for much less than one year, the solid cancer risks emerge. Currently, more delicate platelet inhibition, and shorter exposure to dual oral antiplatelet agents should prevail.
dc.relation.ispartofseries Thrombosis and Haemostasis
dc.subject Aspirin
dc.subject Cancer
dc.subject Clinical trials
dc.subject Clopidogrel
dc.subject Duration of antiplatelet therapy
dc.subject Prasugrel
dc.subject Ticagrelor
dc.subject Triple antiplatelet therapy
dc.subject Vorapaxar
dc.title Solid cancers after antiplatelet therapy: Confirmations, controversies, and challenges
dc.type Article
dc.relation.ispartofseries-issue 6
dc.relation.ispartofseries-volume 114
dc.collection Публикации сотрудников КФУ
dc.relation.startpage 1104
dc.source.id SCOPUS03406245-2015-114-6-SID84948844774


Файлы в этом документе

Данный элемент включен в следующие коллекции

  • Публикации сотрудников КФУ Scopus [24551]
    Коллекция содержит публикации сотрудников Казанского федерального (до 2010 года Казанского государственного) университета, проиндексированные в БД Scopus, начиная с 1970г.

Показать сокращенную информацию

Поиск в электронном архиве


Расширенный поиск

Просмотр

Моя учетная запись

Статистика